# Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

> **NCT00997477** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Foradil Combi (Formoterol-budesonide)

## Key facts

- **NCT ID:** NCT00997477
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997477, "Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00997477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*